SG11202103622SA - Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same - Google Patents

Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same

Info

Publication number
SG11202103622SA
SG11202103622SA SG11202103622SA SG11202103622SA SG11202103622SA SG 11202103622S A SG11202103622S A SG 11202103622SA SG 11202103622S A SG11202103622S A SG 11202103622SA SG 11202103622S A SG11202103622S A SG 11202103622SA SG 11202103622S A SG11202103622S A SG 11202103622SA
Authority
SG
Singapore
Prior art keywords
preparing
same
vaccine composition
combination vaccine
reduced dose
Prior art date
Application number
SG11202103622SA
Other languages
English (en)
Inventor
Inder Jit Sharma
Kumar Rakesh
Jaganathan Semburakkiannan Kilvani
Manohar Doddapaneni
Anil Vyankatrao Shitole
Original Assignee
Serum Inst Of India Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Inst Of India Private Ltd filed Critical Serum Inst Of India Private Ltd
Publication of SG11202103622SA publication Critical patent/SG11202103622SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0016Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/099Bordetella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/13Poliovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K2039/10Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202103622SA 2018-10-12 2019-10-04 Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same SG11202103622SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821038850 2018-10-12
PCT/IN2019/050737 WO2020075184A1 (en) 2018-10-12 2019-10-04 Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same

Publications (1)

Publication Number Publication Date
SG11202103622SA true SG11202103622SA (en) 2021-05-28

Family

ID=68542707

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103622SA SG11202103622SA (en) 2018-10-12 2019-10-04 Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same

Country Status (21)

Country Link
US (1) US20210346483A1 (ko)
EP (1) EP3863665A1 (ko)
JP (1) JP7478144B2 (ko)
KR (1) KR20210091158A (ko)
CN (1) CN113164577B (ko)
AR (1) AR116631A1 (ko)
AU (1) AU2019359564A1 (ko)
BR (1) BR112021006707A2 (ko)
CA (1) CA3115803A1 (ko)
CO (1) CO2021004556A2 (ko)
EA (1) EA202190778A1 (ko)
JO (1) JOP20190242A1 (ko)
MD (1) MD4890B1 (ko)
MX (1) MX2021004233A (ko)
PE (1) PE20211648A1 (ko)
PH (1) PH12021550812A1 (ko)
SG (1) SG11202103622SA (ko)
TW (1) TW202034948A (ko)
UY (1) UY38412A (ko)
WO (1) WO2020075184A1 (ko)
ZA (1) ZA202103154B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
CN112316126B (zh) * 2020-10-29 2021-08-13 武汉生物制品研究所有限责任公司 一种氢氧化铝佐剂吸附百日咳菌毛(Fim)抗原制品的制备方法
CN116355083B (zh) * 2023-05-30 2023-09-08 国药中生生物技术研究院有限公司 特异性结合脊髓灰质炎病毒i型抗原的抗体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU648509B2 (en) * 1989-07-14 1994-04-28 Wyeth Holdings Corporation Stable vaccine compositions containing interleukins
ES2118963T3 (es) 1992-05-23 1998-10-01 Smithkline Beecham Biolog Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
CN1146444C (zh) 1995-06-23 2004-04-21 史密斯克莱·比奇曼生物公司 含有吸附于磷酸铝上的多糖偶联抗原的疫苗组合物
US6790445B1 (en) * 1997-02-06 2004-09-14 Merck & Co., Inc. Preservatives for vaccines
JP2002515056A (ja) * 1997-02-06 2002-05-21 メルク エンド カンパニー インコーポレーテッド ワクチン用チメロサールフリー保存剤
DE69735191T2 (de) 1997-09-15 2006-10-05 Sanofi Pasteur Msd Verfahren zur Herstellung multivalenter Impfstoffe
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
EP1004314A1 (fr) 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
US20040258700A1 (en) * 2003-06-23 2004-12-23 Frimann Tine Holland Vaccine formulation with a preservative
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0616226D0 (en) 2006-08-15 2006-09-27 Novartis Ag Processes
PL2097102T3 (pl) 2006-09-07 2012-10-31 Glaxosmithkline Biologicals Sa Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
MX344751B (es) * 2007-11-23 2017-01-05 Shanghai Zerun Biotechnology Co Ltd Genes que codifican para la proteina l1 mayor de la capside del virus del papiloma humano y uso de los mismos.
PE20100365A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
RU2705163C2 (ru) 2011-01-05 2019-11-05 Бхарат Байотек Интернэшнл Лимитед Комбинированная семивалентная вакцина
CN102133396B (zh) * 2011-03-16 2013-10-16 中国人民解放军第三〇二医院 一种疫苗注射剂及其制备方法
MA42317B2 (fr) * 2015-09-16 2021-11-30 Lg Chemical Ltd Composition de vaccin combinée pour administration multiple
WO2018037365A1 (en) * 2016-08-26 2018-03-01 Serum Institute Of India Private Limited Multivalent vaccine composition
SG11202000224SA (en) * 2017-07-18 2020-02-27 Serum Inst Of India Pvt Ltd An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof

Also Published As

Publication number Publication date
EA202190778A1 (ru) 2021-08-05
JP7478144B2 (ja) 2024-05-02
US20210346483A1 (en) 2021-11-11
CO2021004556A2 (es) 2021-04-30
MD4890B1 (ro) 2024-04-30
PH12021550812A1 (en) 2021-11-08
JP2022502469A (ja) 2022-01-11
WO2020075184A1 (en) 2020-04-16
AR116631A1 (es) 2021-05-26
MX2021004233A (es) 2021-08-16
CN113164577B (zh) 2024-06-18
EP3863665A1 (en) 2021-08-18
BR112021006707A2 (pt) 2021-07-27
CN113164577A (zh) 2021-07-23
CA3115803A1 (en) 2020-04-16
ZA202103154B (en) 2022-03-30
UY38412A (es) 2020-04-30
JOP20190242A1 (ar) 2020-04-12
AU2019359564A1 (en) 2021-06-03
TW202034948A (zh) 2020-10-01
KR20210091158A (ko) 2021-07-21
MD20210028A2 (ro) 2021-11-30
PE20211648A1 (es) 2021-08-24

Similar Documents

Publication Publication Date Title
GB201814362D0 (en) Composition and process for preparing vaccine
ZA202103154B (en) Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same
SG11202003800YA (en) Zika vaccines and immunogenic compositions, and methods of using the same
SG11202010821TA (en) Vaccine composition
IL290999A (en) hbv vaccines and hbv treatment methods
SG11202004863QA (en) Zika vaccines and immunogenic compositions, and methods of using the same
IL291601A (en) Neoglycoconjugates as vaccines and therapeutic tools
EP3854417A4 (en) COMPOSITION FOR VACCINE AGAINST SWINE FEVER AND METHOD FOR PREPARATION
IL275849B (en) Influenza virus vaccines and their uses
IL284233A (en) Norovirus vaccine: formulations and methods
EP3830109A4 (en) METHODS AND COMPOSITIONS FOR ALPHAVIRUS VACCINATION
EP3730620A4 (en) CROSS-IMMUNIZATION ANTIGENIC VACCINE AND PROCESS FOR PREPARATION
SG11201911930SA (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
GB201910794D0 (en) Vaccine
IL284249A (en) A preparation that includes a vaccine additive
IL258700A (en) An excipient and a vaccine that includes it
IL282245A (en) Methods and compositions of polypeptide-based vaccines
ZA202105143B (en) Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
IL285618A (en) Adjuvants and vaccine formulations
KR102130925B9 (ko) 면역원성시스템 및 이를 포함한 동물 백신
IL273168A (en) A compound for an epidural vaccine of hepatitis B and its production
SG11202104416YA (en) Emulsion formulation and method for preparing the same
GB201807378D0 (en) Vaccine composition
GB201807376D0 (en) HMCV Vaccine Composition
GB201803388D0 (en) Polypeptide and vaccine